Denali Therapeutics Inc. Stock News

Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 1,427 shares of the company’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $19.49, for

Denali Therapeutics Inc (NASDAQ:DNLI) CFO Steve E. Krognes sold 1,428 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $19.48, for a

Great West Life Assurance Co. Can acquired a new position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent 13F filing with the

Bamco Inc. NY reduced its position in Denali Therapeutics Inc (NASDAQ:DNLI) by 3.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 952,957 shares of the company’s stock after sel

Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have earned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. Four analysts have r

Algert Global LLC purchased a new position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Ex

Denali Therapeutics (NASDAQ:DNLI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the s

Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a ve

Citigroup Inc. reduced its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 77.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The

Denali Therapeutics (NASDAQ:DNLI) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Friday, ValuEngine reports. Several other r

Cantor Fitzgerald reaffirmed their neutral rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a report published on Wednesday morning, Zacks.com reports. DNLI has been the topic of several other

Denali Therapeutics (NASDAQ:DNLI) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports. A n

Evercore ISI upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from an in-line rating to an outperform rating in a research report sent to investors on Friday morning, Briefing.com Automated Import

IDEAYA Biosciences (NASDAQ:IDYA) initiated with Buy rating and $12 (192% upside) price target at Roth Capital.Menlo Therapeutics (NASDAQ:MNLO) resumed with Overweight rating and $15 (466% upside) at C

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...